Steen Lisby
Copenhagen, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 29, 2016
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL.
Journal: Leukemia & lymphoma
Published: November 11, 2016
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
Journal: Leukemia & lymphoma
Published: October 13, 2016
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Journal: The New England journal of medicine
Published: October 06, 2016
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Journal: Blood
Published: July 07, 2016
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
Journal: The Lancet. Haematology
Published: May 25, 2016
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
Journal: Leukemia & lymphoma
Published: January 20, 2016
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Journal: Lancet (London, England)
Published: January 19, 2016
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
Journal: The New England journal of medicine
Published: August 27, 2015
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.
Journal: The Lancet. Oncology
Published: May 03, 2015
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
Journal: Lancet (London, England)
Published: April 18, 2015
Last Updated: 09/26/2026